Haemostatic complications in haemodialysis patients: Effect of type of vascular access and dialysis filter

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 63, Issue 2, 2003, Pages 127-134

  Yu, Anna ^a,d   Egberg, N ^b   Jacobson, S H ^c  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Karolinska Stockholm CF Centre   (Sweden)

^d Huslakargruppen Taby Vardcentral   (Sweden)

Author keywords

Bleeding; Blood coagulation; C reactive protein; Fibrin D dimer; Heparin; Inflammation; Prothrombin fragment 1 + 2; Tissue factor

Indexed keywords

BIOLOGICAL MARKER; FIBRIN; PROTHROMBIN; THROMBOPLASTIN;

ADULT; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CATHETER; CAUSE OF DEATH; DIALYSIS; FEMALE; FILTER; HEMODIALYSIS; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; ISCHEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSTHESIS; THROMBOEMBOLISM; THROMBOSIS; VASCULAR ACCESS; VASCULAR DISEASE;

FISTULA;

EID: 0038216579     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510308577     Document Type: Article

References (25)

1. Malyszko J, Malyszko JS, Mysliwiec M. Comparison of hemostatic disturbances between patients on CAPD and patients on hemodialysis. Perit Dial Int 2001; 21: 158-65.
2. Ambuhl PM, Wuthrich RP, Korte W, Schmid L, Krapf R. Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation. Nephrol Dial Transplant 1997; 12: 2355-64.
3. Eberst ME, Berkowitz LR. Hemostasis in renal disease: pathophysiology and management. Am J Med 1994; 96: 168-79.
4. Remuzzi G, Perico N, Zoja C, Corna D, Macconi D, Vigano G. Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. J Clin Invest 1990; 86: 1768-71.
5. Gouin-Thibauh I, Samama MM. Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Hemost 1999; 25: 167-72.
6. Cioni G, Cristani A, Mussini C, Grandi S, Pentore R, Zeneroli ML, Tizzanini W, Zagni G, Ventura E. Incidence and clinical significance of elevated fibrin(ogen) degradation product and/or D-dimer levels in liver cirrhosis patients. Ital J Gastroenterol 1990; 22: 70-4.
7. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 640-4.
8. Miozzari M, Wahl C. D-dimers in hemodialysis patients. Nephron 2001; 88: 278-9.
9. Sagripanti A, Cupisti A, Baicchi U, Ferdeghini M, Morelli E, Barsotti G. Plasma parameters of the prothrombotic state in chronic uremia. Nephron 1993; 63: 273-8.
10. Chojnowski K, Trelinski J, Wawrzyniak E, Sobolewska M, Mielicki W. Assessment of coagulation disorders and cancer procoagulant activity in patients with myelodysplastic syndromes. Neoplasma 2002; 49: 155-8.
11. Giannitsis E, Siemens HJ, Mitusch R, Tettenborn I, Wiegand U. Schmucker G, Sheikhzadeh A, Stierle U. Prothrombin fragments F1 + 2, thrombin-antithrombin III complexes, fibrin monomers and fibrinogen in patients with coronary atherosclerosis. Int J Cardiol 1999; 68: 269-74.
12. Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van VI, Demunck H, Kasper M, Breier G, Evrard P, Muller M, Risau W, Edgington T, Collen D. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383: 73-5.
13. Tremoli E, Camera M, Toschi V, Colli S. Tissue factor in atherosclerosis. Atherosclerosis 1999; 144: 273-83.
14. More L, Sim R, Hudson M, Dhillon AP, Pounder R, Wakefield AJ. Immunohistochemical study of tissue factor expression in normal intestine and idiopathic inflammatory bowel disease. J Clin Pathol 1993; 46: 703-8.
15. Ertenli I, Kiraz S, Celik IC, Haznedaroglu C, Erman M, Calguneri M, Kirazli S. Changes in the concentration and distribution of tissue factor pathway inhibitor in Behçet's disease and systemic lupus erythematosus: effect on the prethrombotic state. Ann Rheum Dis 1993; 60: 1149-51.
16. Samad F, Pandey M, Loskutoff DJ. Regulation of tissue factor gene expression in obesity. Blood 2001; 98: 3353-8.
17. Castillo R, Lozano T, Escolar G, Revert L, Lopez J, Ordinas A. Defective platelet adhesion on vessel subendothelium in uremic patients. Blood 1986; 68: 337-42.
18. Escolar G, Cases A, Bastida E, Garrido M, Lopez J, Revert L, Castillo R, Ordinas A. Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa. Blood 1990; 76: 1336-40.
19. Salvati F, Liani M. Role of platelet surface receptor abnormalities in the bleeding and thrombotic diathesis of uremic patients on hemodialysis and peritoneal dialysis. Int J Artif Organs 2001; 24: 131-5.
20. Casonato A, Pontara E, Vertolli UP, Steffan A, Durante C, De ML, Sartorello F, Girolami A. Plasma and platelet von Willebrand factor abnormalities in patients with uremia: lack of correlation with uremic bleeding. Clin Appl Thromb Hemost 2001; 7: 81-6.
21. Andrassy K, Ritz E. Uremia as a cause of bleeding. Am J Nephrol 1985; 5: 313-9.
22. Pales JL, Lopez A, Asensio A, Merola E, Company X, Deulofeu R, Garcia M, Balague A. Inhibitory effect of peak 2-4 of uremic middle molecules on platelet aggregation. Eur J Haematol 1987; 39: 197-202.
23. Fayed HM, Kame MA, Sultan MM, Mowafy MN, Helmy SM, El-Zoghby MH. Nitric oxide generation by peripheral blood cells in chronic renal failure. Br J Biomed Sci 2002; 59: 24-9.
24. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16: 1-20.
25. Taylor JE, Belch JJ, McLaren M, Henderson IS, Stewart WK. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients. Kidney Int 1993; 44: 182-90.